Post Profile






'Epigenetic' Drug May Boost Success of PARP Inhibitor Treatment for Certain Leukemias and Breast Cancers

Drugs called PARP inhibitors, which sabotage cancer cells' ability to repair damage to their DNA, have shown some promise in treating human breast cancers that contain BRCA1 and BRCA2 gene mutations. Now, a new study in lab-grown cancer cells and mice suggests that their effectiveness could be strengthened and expanded to other forms of breast cancer and leukemia not linked to BRCA mutations by adding a so-called epigenetic drug.
read more

share

Related Posts


Cisplatin-Resistant Cancer Cells Sensitive To Experimental Anticancer Drugs Called PARP Inhibitors

Health : Medical News Today

Cisplatin-resistant non-small cell lung cancer cells expressed high levels of hyperactivated PARP1. Cells succumbed to PARP inhibitors in vitro. PARP inhibitor slowed cisplatin-resistant tumor growth in mice. Poly (ADP-ribose) polym...

New resistance mechanism to chemotherapy in breast and ovarian cancer

Academics / General Science : ScienceDaily: Science Society

A new study explains why tumors with BRCA1 and BRCA2 mutations stop responding to PARP inhibitor drugs.

Small molecule inhibitor shows promise in precision cancer targeting

Academics / General Science : ScienceDaily: Science Society

Cancer cells with BRCA1 or BRCA2 gene mutations are key targets for cancer therapeutics. Yet, few agents can selectively eliminate cells deficient in BRCA, and none can do so without the risk of inducing drug resistance. Now scienti...

New mechanism of action for PARP inhibitors discovered

Academics / General Science : Science Codex

PHILADELPHIA — New understanding of how drugs called PARP inhibitors, which have already shown promise for the treatment of women with familial breast and ovarian cancers linked to BRCA mutations, exert their anticancer effects has ...

'PARP' drug sabotages DNA repair in pre-leukemic cells

Academics / General Science : Science Codex

Looking for ways to halt the uncontrolled growth of cancer cells, scientists at Johns Hopkins have found that a new class of drugs, called PARP inhibitors, may block the ability of pre-leukemic cells to repair broken bits of their o...

Comments


Copyright © 2016 Regator, LLC